Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab. Clinical data from a phase 1 trial with lumiliximab demonstrated an acceptable toxicity profile in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). We therefore pursued a phase 1/2 dose-escalation study of lumiliximab added to fludarabine, cyclophosphamide, and rituximab (FCR) in previously treated CLL patients.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia 1 . CLL cells express the B-cell markers CD19, CD20, CD23, and sIg (dim) with co-expression of the T-cell marker CD5. 2 Recent data indicate that select genetic features, including interphase cytogenetics, immunoglobulin gene mutational status, and ZAP-70 expression, contribute to the heterogeneity of CLL and potentially influence prognosis. [3] [4] [5] [6] Several of these prognostic features may impact treatment response and response duration. [7] [8] [9] [10] [11] Despite the identification of these important prognostic features, treatment of CLL is initiated only at time of symptomatic disease because early treatment has not been shown to convey a survival advantage.
The initial treatment of symptomatic CLL has evolved significantly over the past decade.
Monotherapy with chlorambucil or fludarabine have both been shown to be inferior to the combination of fludarabine and cyclophosphamide (FC) with respect to overall response rate (ORR), complete response (CR) rate, and progression-free survival (PFS) in younger patients with CLL.
CLL cells. 18, 19 Lumiliximab induces similar levels of apoptosis to rituximab in CD23-bearing lymphoid cell lines and CLL cells following secondary cross-linking, and prolongs survival of SCID mice inoculated with CD23-bearing lymphoblastic cell lines. 20 In preclinical studies, lumiliximab was shown to enhance the effects of fludarabine and rituximab, providing a rationale for combining lumiliximab with regimens containing fludarabine and rituximab in clinical trials in CLL{Pathan, 2008 #203}. As CD23 is expressed on a high proportion of CLL cells but is only minimally expressed on other cells, targeting this molecule provides a treatment modality that is specific to CLL with the potential to minimize additional toxicity. In a 46-patient, phase 1, dose-escalation trial performed in patients with relapsed and refractory CLL, lumiliximab monotherapy was well tolerated at doses of up to 500 mg/m 2 given three-times per week for 4 weeks. 21 Although no CRs or PRs were noted in this trial, evidence of disease reduction was observed in a subset of patients. 21 Seventeen of 33 patients (52%) had a decrease in lymph node bulk and 42 of 46 patients (91%) had modest reduction in lymphocytosis. However, these effects were transient with most patients progressing by 2 months after therapy. No additional benefit was observed with the more frequent dosing regimens at 500 mg/m 2 . The recommended dose for future studies of lumiliximab in combination with other agents was 500 mg/m 2 .
Based upon this favorable safety profile and preclinical enhancement of the antitumor effect of both rituximab and fludarabine, 20 we sought to perform a phase 1/2 study adding lumiliximab to the FCR regimen for patients with previously treated CLL. We hypothesized that lumiliximab might enhance the effectiveness of FCR-based therapy without exacerbating the toxicity observed with FCR. 
Materials and Methods

Patients
Pretreatment and serial laboratory assessments
Baseline laboratory assessments included: complete blood count with differential, platelet count, and absolute lymphocyte count; serum chemistries, including liver functions; urinalysis; direct and indirect antibody tests; beta-2-microglobulin; interphase cytogenetics 23 ; and an electrocardiogram. In the absence of disease progression, patient samples for complete blood count and serum chemistry measurements were collected biweekly during the treatment period, monthly during the posttreatment follow-up period up to month 12, every 3 months after month 12 to the end of year 2, and then every 6 months after year 2 to the end of year 4. CT-scans were not performed as part of the response evaluation criteria.
Treatment
Patients were assigned sequentially to cohorts 1, 2, or phase 2 expansion, and received up to 6 cycles (according to tolerability/disease progression) of lumiliximab plus FCR at intervals of 28 days.
Stepped-up dosing of rituximab and lumiliximab was given for all patients in cycle 1. Patients in 
Criteria for dose escalation
A standard 3+3 dose-escalation schema was followed with the plan to escalate from the cohort 1 to 
Response assessments
Patients were assessed for response at weeks 13 and 25. The primary efficacy variable in this study was ORR, defined as the percentage of patients with response classified as CR or PR, using the NCIWG 96 criteria for CLL.
Pharmacokinetics
Serum for lumiliximab and rituximab pharmacokinetics were collected pre-infusion, 10 minutes, 1 hour, 2 hours, and 24 hours after the completion of the infusion on study days 1, 3, and 4 of cycle 1, and on day 1 of cycles 3 and 6. Additional samples were collected before the treatment on day 3 of cycles 3 and 6, and on day 1 of weeks 3, 5, 11, 13, 23, and 25. Total serum concentrations of lumiliximab were determined using a validated ELISA developed by Biogen Idec, in which a monoclonal anti-lumiliximab antibody was used as the capture reagent, followed by a blocking step and incubation with standards, controls, and patient samples. Lumiliximab in patient samples was detected by the addition of antihuman IgG-horseradish peroxidase (Southern Biotech, Birmingham, AL); color was developed with tetramethylbenzidine substrate, and lumiliximab concentrations were calculated by extrapolation from a four-parameter standard curve. The assay was validated according to International Conference on Harmonization guidelines, and had a lower limit of quantitation of 450 ng/mL. Total serum concentrations of rituximab were determined using a validated ELISA developed by Biogen Idec, in which a polyclonal anti-rituximab antibody was used as the capture reagent, followed by a blocking step and incubation with standards, controls, and patient samples.
Rituximab in patient samples was detected by the addition of antihuman IgG-horseradish peroxidase (Southern Biotech); color was developed with ABTS substrate, and rituximab concentrations were 
Anti-lumiliximab antibodies
A validated anti-lumiliximab ELISA developed by Biogen Idec was used to determine the concentration of human antibody to lumiliximab in serum. Lumiliximab was used as a capture reagent. After overnight incubation, plates were blocked then incubated with standards, controls, and patient samples. Anti-lumiliximab antibodies were detected using lumiliximab conjugated to horseradish peroxidase and tetramethylbenzidine as the substrate. Samples were tested at baseline and at weeks 13, 25, 41, and at month 12 after the first dose of lumiliximab. The lower limit of quantitation for this assay was 400 ng/mL of anti-lumiliximab antibody.
Anti-rituximab antibodies
A validated human anti-chimeric antibody (HACA) specific ELISA developed by Biogen Idec was used to determine the concentration of anti-rituximab antibody in serum. A chimeric monoclonal antibody was used as a capture reagent. After overnight incubation, plates were blocked and then For personal use only. on April 20, 2017. by guest www.bloodjournal.org From incubated with standards, controls, and patient samples. Human anti-chimeric antibodies were detected using a biotinylated monoclonal chimeric antibody, streptavidin-horseradish peroxidase, and tetramethylbenzidine substrate. Samples were tested at baseline and at weeks 13, 25, 41, and at month 12 after the first dose of rituximab.
Interphase cytogenetic analysis
Peripheral blood or bone marrow samples were cultured for 3 days with Pokeweed mitogen (final concentration 10 µL/mL; Sigma Aldrich, St Louis, MO) and phorbol 12-myristic 13-acetate (final concentration 40 ng PMA/mL; Sigma Aldrich) to stimulate the B cells. Harvest and slide making were by standard laboratory procedures. Probes for FISH were D12Z1 (12 centromere), TP53 (17p13.1), ATM (11q22.3), and D13S319 (13q14), all from Abbott Molecular (Des Plaines, IL), and were used according to the manufacturer's directions.
Statistical methods
Statistical analyses were performed using SAS statistical software, version 9.0. Adverse events were coded using MedDRA, version 11.0. Response rates were summarized using frequencies and percentages with 95% confidence intervals by exact binomial methods. Median time-to-event measures and graphs for time-to-event variables were generated using Kaplan-Meier methodology, with 95% confidence intervals by the sign test. PFS was measured from the day of registration until progression, relapse, or death due to any cause. Statistical testing was not performed.
Results
Patient baseline characteristics
Thirty-one patients gave consent and were treated at 5 clinical sites. Patient baseline characteristics are summarized in Table 1 . The median age was 58 years with 8 patients being at least 65-years-old.
The majority of patients (71%) had Rai stage I/II disease and the median beta-2-microglobulin level was 3.3 µg/mL. The median number of therapies was 2 with 61% of patients having received fludarabine. Three subjects were refractory to fludarabine, as defined by failure to achieve a complete 
Toxicity assessments
Eight patients(26%) experienced grade 3, and 12 patients(39%) experienced grade 4 toxicities considered to be related to the study treatment (Table 2 ). These toxicities were those typically expected with the chemoimmunotherapy regimen. There were no DLTs and, as CD23 saturation was complete and sustained at the 500 mg/m 2 lumiliximab dose, 21 no escalation above this dose was performed.
Infections are common in active CLL and, not unexpectedly, were observed in patients participating in this trial. During treatment, three grade 3 infections (a clostridial infection, a cytomegalovirus infection, and a bacterial wound infection) were observed. All other infections were grade 1 or 2, with upper respiratory sites being most common.
The proportion of cycles completed was: 1-3 cycles in 11 patients (35%); 4 cycles in 3 patients (10%); and 5 cycles in 2 patients (6%). Fifteen patients (48%) completed the intended 6 cycles of therapy. Nine patients (29%) discontinued therapy due to cytopenia, two of whom had neutropenic fever.
Response and response duration
Of the 31 patients enrolled, 20 (65%) exhibited a confirmed CR or PR by NCIWG 96 criteria. Sixteen of 31 patients (52%) attained a CR, including normocellular marrow, and normal neutrophil and had not yet died or demonstrated progression at the time of this analysis (January 9, 2009) and continue to be followed-up for PFS and DR. These patients were censored for these analyses. Twentysix of the 31 patients discontinued the study before the end of the 4-year follow-up period: 24 due to disease progression requiring subsequent CLL therapy; 1 for personal reasons; and 1 due to death.
Twelve patients died during long term follow-up; 9 deaths were due to disease progression.
Response by interphase cytogenetics
Several studies have demonstrated the importance of interphase cytogenetics in predicting response and response duration of combined chemoimmunotherapy, and have recently gained acceptance in the community. Therefore we assessed the status of the most common abnormalities observed in CLL.
Using the Döhner prioritization schema, 3 
Pharmacokinetics
Across both lumiliximab dose cohorts, 19 (61%), 15 (48%), and 10 (32%) of 31 patients at cycles 1, 3, and 6, respectively, had measurable concentrations that permitted the calculation of pharmacokinetic variables for lumiliximab. Similarly, 22 (71%), 15 (48%), and 10 (32%) patients had measurable concentrations of rituximab that permitted pharmacokinetic calculations from cycles 1, 3, and 6, respectively. Mean ± standard deviation serum concentrations over time for patients treated with 500 mg/m 2 of lumiliximab are shown in Figure 2 , and pharmacokinetic parameters are provided in Table 3 . Volume of distribution for both lumiliximab and rituximab were similar to plasma volume.
Clearance of both antibodies was reduced with continued treatment resulting in increases in the halflife and AUC values. C max roughly doubled for both lumiliximab and rituximab from cycle 1 to 6. 
Anti-lumiliximab and anti-rituximab antibodies
Thirteen of the 31 treated patients had evaluations of serum anti-lumiliximab antibodies and antirituximab antibodies measured at both baseline and at least one post-dose time point (weeks 13, 25, 41, or month 12). All measured values were undetectable.
Discussion
This is the first study of lumiliximab in combination with FCR in patients with relapsed or refractory CLL. Treatment with lumiliximab combined with FCR was well tolerated, resulted in a high number of patients with a durable CR, and was not associated with increased infectious risk or prolonged cytopenias compared with historical controls. 14 may represent an exciting new therapy for CLL that warrants further study. However, it must also be considered that differences in the eligibility criteria, such as the exclusion of patients with pre-existing neutropenia or thrombocytopenia, and/or differences in baseline characteristics between the previously reported FCR study and this trial relative to median platelet count, mean beta-2-microglobulin, and proportion of patients with Rai stage III/IV disease could explain this. 14, 24 have demonstrated that pretreatment thrombocytopenia and Rai stage disease may influence treatment response. Therefore, determining the influence of the addition of lumiliximab to FCR-based chemoimmunotherapy in previously treated CLL will require a randomized trial.
Several trials in relapsed CLL
The clearance of both lumiliximab and rituximab were observed to decrease throughout the treatment period resulting in increased half-life and increased exposure to the antibodies. Overall, these data combined with the preclinical data provide a rationale for further investigation of lumiliximab in combination with FCR, as part of a randomized trial to determine the true added benefit of lumiliximab combined with FCR as a combination therapy for patients with relapsed CLL.
For
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